The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?
暂无分享,去创建一个
A. Capucci | G. Boriani | A. Rapacciuolo | L. Padeletti | A. Vado | S. Valsecchi | A. Vicentini | E. Pisano | G. Forleo | F. Solimene | G. Botto | P. Palmisano | A. D'onofrio | M. Viscusi | A. Talarico | T. Infusino | G. Russo | P. Ferrari | G. Bertero | M. Lovecchio | A. D’Onofrio | E. Pisanò | Mariolina Lovecchio
[1] Jagmeet P. Singh,et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] Andrea Mazzanti,et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.
[3] Paul A. Belk,et al. Severe Atrioventricular Decoupling, Uncoupling, and Ventriculoatrial Coupling During Enhanced Atrial Pacing: Incidence, Mechanisms, and Implications for Minimizing Right Ventricular Pacing in ICD Patients , 2008, Journal of cardiovascular electrophysiology.
[4] I. Ranasinghe,et al. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation , 2016, Annals of Internal Medicine.
[5] Arjun D. Sharma,et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. , 2005, Heart rhythm.
[6] W. Stevenson,et al. Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical review. , 2012, European heart journal.
[7] Pier D. Lambiase,et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. , 2015, Journal of the American College of Cardiology.
[8] H. Putter,et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice , 2013, Heart.
[9] Lluís Mont,et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.
[10] A. Auricchio,et al. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. , 2016, Heart rhythm.
[11] Wojciech Zareba,et al. Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.
[12] J. Day,et al. Is Dual-Chamber Programming Inferior to Single-Chamber Programming in an Implantable Cardioverter-Defibrillator?: Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) Study , 2006, Circulation.
[13] A. Wilde,et al. Communicating Antitachycardia Pacing-Enabled Leadless Pacemaker and Subcutaneous Implantable Defibrillator. , 2016, Journal of the American College of Cardiology.
[14] Mark Kremers,et al. Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator , 2013, Circulation.
[15] G. Boriani,et al. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2016]. , 2018, Giornale italiano di cardiologia.
[16] L. Jordaens,et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. , 2012, American heart journal.
[17] P. Lambiase,et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.
[18] M. Chung,et al. Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures: Results From the REPLACE Registry , 2010, Circulation.
[19] Eugene Crystal,et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. , 2010, Journal of the American College of Cardiology.
[20] N. Hawkins,et al. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] J. Nielsen,et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .
[22] S. Boveda,et al. Implantation of subcutaneous implantable cardioverter defibrillators in Europe: results of the European Heart Rhythm Association survey. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[23] J. Healey,et al. Wilkoff BL, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.